There were several updates in the field of liver cancer in 2020. Here, CURE® looks back at some news and updates in the field of liver cancer that patients may have missed.
- Treatment with Opdivo (nivolumab) with Yervoy (ipilimumab) was manageably safe and resulted in a promising response in patients with advanced hepatocellular carcinoma (HCC) previously treated with Nexavar (sorafenib). READ MORE.
- The combination of Tafinlar (dabrafenib) plus Mekinist (trametinib) could offer patients with BRAF V600E-mutated biliary tract cancer another much-needed treatment option, according to results from a phase 2 study published in the Lancet Oncology. READ MORE.
- A survey administered by pharmaceutical company Incyte and the nonprofit Cholangiocarcinoma Foundation found that patients with bile duct cancer face more than a dozen symptoms or treatment-related side effects that negatively affect their daily lives. READ MORE.
- The Food and Drug Administration’s approval of Pemazyre (pemigatinib) in May was a “huge milestone” for patients with cholangiocarcinoma, according to the advocacy coordinator with the Cholangiocarcinoma Foundation. READ MORE.
- Racial inequities in the liver cancer death rate, which previously had been declining, started rising after lifesaving drugs became available to treat hepatitis C virus, a major risk factor for the cancer. READ MORE.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.